AIFM2 and cancer: Specifically, analyses of the Cancer Therapeutics Response Portal (CTRP)27–29 revealed that FSP1 (also known as AIFM2) exhibited the most striking positive correlation with resistance to multiple class 2 FINs that inactivate GPX4, including RSL3, ML162, and ML210 (Supplementary Fig. 3a), which is consistent with recent reports that FSP1 acts in parallel to GPX4 to inhibit ferroptosis30,31.